U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06899802) titled 'A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine' on March 06.
Brief Summary: This phase 2 clinical trial will investigate an optimal dose, dosing regimen, and evaluate reactogenicity, safety and immunogenicity in healthy adult participants of the recombinant, multivalent MVA-BN-WEV vaccine. MVA-BN-WEV is intended for active immunization for prevention of disease induced by VEEV and EEEV, in persons aged 18 years and older at high risk of exposure.
Study Start Date: March 10
Study Type: INTERVENTIONAL
Condition:
Encephalitis
Intervention:
BIOLOGICAL: MVA-BN-WEV
MVA-mBN396 (common name MVA-B...